HJKC3-0003
Phase II
OPEN TO ACCRUAL
Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
NOVARTIS-CABL001A2001B
Phase IV
OPEN TO ACCRUAL *
An Open-Label, Multi-Center Asciminib Roll-Over Study to Assess Long-Term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued Treatment